21-minute watch
EHA 2025
Age is not a barrier: The older patient with comorbidities
Dr Mary Ann Anderson
24-minute watch
EHA 2025
Timing is of the essence: The patient with MCL on a BTKi
Dr Martina Pennisi
8-minute watch
EBMT 2025
Charting a course in the CAR T age: SoC in 2L R/R DLBCL
Professor Fabio Ciceri
10-minute watch
EHA: How is CAR T evolving?
Why should CAR T be used earlier in R/R DLBCL?
Dr Claire Roddie
11-minute watch
EHA: How is CAR T evolving?
What does the future hold for CAR T manufacturing?
Dr Carl June
13-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
CAR T survivorship and summary
Prof. Graham Collins, Dr Mariana Bastos-Oreiro, Dr Pierre Sesques
18-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
Choosing CAR T with curative intent
Dr Natasha Kekre
10-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
Delivering CAR T
Dr Pierre Sesques
23-minute watch
EHA: Follow the patient pathway to survival in 2L DLBCL
Planning ahead for 2L
Prof. Graham Collins, Dr Mariana Bastos-Oreiro
14-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
Diagnosis, treatment and recovery: Perspectives from a patient and a psychotherapist
Ms Surabhi Chaturvedi, Dr Wendy Osborne
24-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
How can we bring CAR T’s curative potential to more patients?
Ms Surabhi Chaturvedi, Dr Suzanne van Dorp
14-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
What is the most appropriate treatment choice in 2L LBCL? A case-based approach
Dr Wendy Osborne
20-minute watch
CAR T: Improving survival with the SoC in 2L LBCL
Why has CAR T become the SoC in 2L LBCL?
Dr Anna Sureda
15-minute watch
EU CAR T: Kite symposium
How can we improve survival outcomes in R/R LBCL?
Dr Cathy Burton
15-minute watch
EU CAR T: Kite symposium
How has CAR T changed survival outcomes in LBCL so far?
Dr Pere Barba, Prof. Peter Vandenberghe
5-minute watch
EU CAR T: Access and reimbursement to CAR T-cell therapy
How can we address reimbursement challenges for CAR T?
Adam Hutchings
4-minute watch
EU CAR T: Access and reimbursement to CAR T-cell therapy
Why is timely reimbursement of CAR T important for our patients?
Anuradha Rajapakse
3-minute watch
EU CAR T: Expert Perspective
Secondary malignancies after Car T-cell therapy
Dr Anna Sureda
5-minute watch
ASH 2024
Outpatient administration of axi-cel: updates from ZUMA-24 and RWE
Dr Lori Leslie
3-minute watch
ASH 2024
ALYCANTE: HRQOL post-CAR T in transplant-ineligible patients
Dr Pierre Sesques
5-minute watch
ASH 2024
CAR-Tography: getting a better understanding of acute toxicities post-CAR T
Dr Kai Rejeski
4-minute watch
ASH 2024
Can interim PET aid early identification of patients for CAR T?
Prof. Ran Reshef
3-minute watch
ASH 2024
What approaches are being used to prevent and mitigate CAR T toxicities?
Dr Marcela Maus
5-minute watch
ASH 2024
How is MCL managed with CAR T? Results from the EBMT survey
Dr Gloria Iacoboni
3-minute watch
Prof. Graham Collins: Expert perspective
Centre qualification process
Prof. Graham Collins
1-minute watch
Prof. Graham Collins: Expert perspective
Referral considerations
Prof. Graham Collins
4-minute watch
Prof. Graham Collins: Expert perspective
RTC and QTC collaborations
Prof. Graham Collins
4-minute watch
Prof. Graham Collins: Expert perspective
RTC and QTC relationships
Prof. Graham Collins
5-minute watch
Prof. Graham Collins: Expert perspective
Preparing the patient for CAR T
Prof. Graham Collins
3-minute watch
ASCO, EHA & ICML: Expert perspective
Emerging practice-changing data in haematological malignancies
Prof. Max Topp
2-minute watch
ASCO, EHA & ICML: Expert perspective
The effect of bendamustine bridging on CAR T outcomes
Dr Gloria Iacoboni
4-minute watch
ASCO, EHA & ICML: Expert perspective
Highlights of summer congresses
Dr Matthew Lunning
2-minute watch
ASCO, EHA & ICML: Expert perspective
Is there a role for consolidation radiotherapy in primary mediastinal large B‑cell lymphoma?
Dr Wendy Osborne
4-minute watch
ASCO, EHA & ICML: Expert perspective
Updates on front‑line management in NHL
Prof. Christopher Fox
10-minute watch
ASCO, EHA & ICML: Expert perspective
Brexucabtagene autoleucel in R/R B‑cell acute lymphoblastic leukaemia: Real‑world data
Dr Bijal Shah
3-minute watch
ASCO, EHA & ICML: Expert perspective
Real-world data supporting CAR T‑cell therapy in non‑Hodgkin's lymphoma
Dr Robin Sanderson
3-minute watch
ASCO, EHA & ICML: Expert perspective
CAR T‑cell therapy in the management of primary CNS lymphoma
Dr Kate Cwynarski
3-minute watch
ASCO, EHA & ICML: Expert perspective
Latest data from CAR T‑cell therapy and bispecific antibody use in DLBCL
Dr Michael Dickinson
2-minute watch
ASCO, EHA & ICML: Expert perspective
Axicabtagene ciloleucel in 2L DLBCL: Implications for future investigation
Dr Jason Westin
2-minute watch
ASCO, EHA & ICML: Expert perspective
ZUMA-7: My key takeaways
Dr Miguel-Angel Perales
3-minute watch
ASCO, EHA & ICML: Expert perspective
ZUMA-7: What is the Q-TWiST analysis?
Dr Miguel-Angel Perales
3-minute watch
ASCO, EHA & ICML: Expert perspective
ZUMA-7: Survival outcomes with axicabtagene ciloleucel in 2L DLBCL
Prof. Marie José Kersten
5-minute watch
ASCO, EHA & ICML: Expert perspective
Supporting patients and caregivers through their CAR T‑cell therapy journey
Ms Lorna Warwick
8-minute watch
ASCO, EHA & ICML: Expert perspective
What is the role of patient prehabilitation prior to CAR T‑cell therapy?
Dr Keith Wilson
12-minute watch
EHA: Tracing the steps to CAR T and beyond
Treatment selection in 2L DLBCL
Dr Sridhar Chaganti
Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023